<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TARCEVAÂ - erlotinib hydrochlorideÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TARCEVA safely and effectively. See full prescribing information for TARCEVA. 
TARCEVA (erlotinib hydrochloride) tablet for oral use 
Initial U.S. Approval: 2004 
 
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and
Precautions, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2</a>)
09/2008 </p>
<p class="Highlighta">Warnings and
Precautions, Hepatotoxicity (<a href="#i4i_section_ID_B53F31A4-1715-47D7-A2E9-69CB5299C84D">5.3</a>)
09/2008 </p>
<p class="Highlighta">Warning and
Precautions, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span> (<a href="#i4i_section_ID_A7441A21-B523-48FB-B03D-6A185C3D982A">5.4</a>)
09/2008 </p>
<p class="Highlighta"> </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">TARCEVA is a tyrosine
kinase inhibitor indicated for the treatment of: </p>
<ul>
<li><p class="Highlighta">Locally advanced or metastatic non-small cell
	lung cancer (NSCLC) after failure of at least one prior chemotherapy
	regimen. (<a href="#i4i_section_ID_A6684C3E-C2A4-48A4-BAF6-8AFBE4637E8A">1.1</a>)
		 </p></li>
<li><p class="Highlighta">First-line
	treatment of patients with locally advanced, unresectable or
	metastatic pancreatic cancer, in combination with gemcitabine. (<a href="#i4i_section_ID_5D2EC15B-2622-4D0C-98EB-EE43DC5F79EE">1.2</a>) </p></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"> </p>
<ul>
<li><p class="Highlighta">The dose for NSCLC is 150 mg/day. (<a href="#i4i_section_ID_C26667F8-C57C-44C8-AFDE-085AF0AE8B20">2.1</a>)
		 </p></li>
<li><p class="Highlighta">The dose for pancreatic cancer is 100 mg/day.
	(<a href="#i4i_section_ID_B362A20D-1DD0-4EB2-AB08-D08C2C6F2D32">2.2</a>)
		 </p></li>
<li><p class="Highlighta">All doses of TARCEVA should be taken at least
	one hour before or two hours after food.Â (<a href="#i4i_section_ID_C26667F8-C57C-44C8-AFDE-085AF0AE8B20">2.1</a>,
	<a href="#i4i_section_ID_B362A20D-1DD0-4EB2-AB08-D08C2C6F2D32">2.2</a>)
		 </p></li>
<li><p class="Highlighta">Reduce in 50 mg
	decrements, when necessary. (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3</a>) </p></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta"> </p>
<ul><li><p class="Highlighta">Tablets: 25 mg,
	100 mg and 150 mg. (<a href="#i4i_dosage_form_strength_ID_3A87C020-36F1-4289-8FFD-8AC4E0654697">3</a>) </p></li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None<br>  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"> </p>
<ul>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (ILD)-like events,
	including fatalities have been infrequently reported. Interrupt
	TARCEVA if acute onset of new or progressive unexplained pulmonary
	symptoms, such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> occur. Discontinue
	TARCEVA if ILD is diagnosed. (<a href="#i4i_section_ID_7E2E1FA3-88F8-4942-9B3A-3DEF35EB2DCC">5.1</a>)
		 </p></li>
<li><p class="Highlighta">Monitor patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>
	closely. Interrupt or discontinue TARCEVA if changes in liver
	function are severe (<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2</a>)
		 </p></li>
<li><p class="Highlighta">Cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and hepatorenal
	syndrome (including fatalities) have been reported. Monitor periodic
	liver function testing. Interrupt or discontinue TARCEVA if liver
	function changes are severe. (<a href="#i4i_section_ID_B53F31A4-1715-47D7-A2E9-69CB5299C84D">5.3</a>)
		 </p></li>
<li><p class="Highlighta">Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (including
	fatalities), and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have been reported.Â Interrupt
	TARCEVA in the event of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Monitor renal function and
	electrolytes in patients at risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. (<a href="#i4i_section_ID_A7441A21-B523-48FB-B03D-6A185C3D982A">5.4</a>)
		 </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> has been
	reported, including fatalities, in patients with pancreatic cancer.
	(<a href="#i4i_section_ID_724C4E07-C0AB-48A0-A30B-33C8C61A1103">5.5</a>)
		 </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accidents</span>, including a
	fatality, have been reported in patients with pancreatic cancer.
	(<a href="#i4i_section_ID_3064DC54-2944-45D7-AE4B-78E3E0B248EF">5.6</a>)
		 </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">Microangiopathic Hemolytic Anemia</span> with
	<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has been reported in patients with pancreatic
	cancer. (<a href="#i4i_section_ID_1174B29B-4BC3-44E4-8415-7B76CA6E8E51">5.7</a>)
		 </p></li>
<li><p class="Highlighta">Women should be advised to avoid pregnancy
	while on TARCEVA. Treatment should only be continued if the
	potential benefit to the mother outweighs the risk to the fetus.
	(<a href="#i4i_section_ID_D2F3C49F-56A4-4CB0-86A0-0B1740C09D6B">5.8</a>)
		 </p></li>
<li><p class="Highlighta">International
	Normalized Ratio (INR) elevations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events, some
	associated with concomitant warfarin administration have been
	reported. Monitor patients taking warfarin or other
	coumarin-derivative anticoagulants. (<a href="#i4i_section_ID_014DBB7E-1FB4-4AAE-AB59-E54A206507AB">5.9</a>) </p></li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">The most common adverse
reactions (&gt;50%) in NSCLC are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and
<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. (<a href="#section-"> 6.1</a>) </p>
<p class="Highlighta">The most common adverse
reactions (&gt;50%) in pancreatic cancer are <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. (<a href="#section-8.2"> 6.2</a>) </p>
<br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact OSI Pharmaceuticals Inc. at 1-800-572-1932<br>or FDA at 1-800-FDA-1088 </span><a href="#S6">or www.fda.gov/medwatch</a>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CYP3A4 inhibitors may increase erlotinib plasma concentrations. (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)</li>
<li>CYP3A4 inducers may decrease erlotinib plasma concentrations. (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)</li>
<li>CYP1A2 inducers may decrease erlotinib plasma concentrations. (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)</li>
<li>Erlotinib solubility is pH dependent. Drugs that alter the pH of the upper GI tract may alter the solubility of erlotinib and hence its absorption. (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)</li>
<li>Cigarette smoking decreases erlotinib plasma concentrations (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)</li>
</ul></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">RECENT MAJOR CHANGES</a></h1>
<h1><a href="#section-1" class="toc">1.  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Non-Small Cell Lung Cancer (NSCLC)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  Pancreatic Cancer</a></h2>
<h1><a href="#section-2" class="toc">2.  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Recommended Dose - NSCLC</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Recommended Dose - Pancreatic Cancer</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Dose Modifications</a></h2>
<h1><a href="#section-3" class="toc">3.  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5.  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Hepatotoxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7  <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">Microangiopathic Hemolytic Anemia</span> with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Use in Pregnancy</a></h2>
<h2><a href="#section-5.9" class="toc">5.9  Elevated International Normalized Ratio and Potential <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h1><a href="#section-6" class="toc">6.  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Non-Small Cell Lung Cancer</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Pancreatic Cancer</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 NSCLC and Pancreatic Cancer Indications</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Gender </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Race</a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.9 Patients with Renal ImpairmentÂ </a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Non-Small Cell Lung Cancer NSCLC â€“ TARCEVA Administered as a Single Agent</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 NSCLC - TARCEVA Administered Concurrently with Chemotherapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Pancreatic Cancer - TARCEVA Administered Concurrently with Gemcitabine</a></h2>
<h1><a href="#section-14" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1.  INDICATIONS AND USAGE</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1 Non-Small Cell Lung Cancer (NSCLC)</h2>
<p class="First"></p>
<p>TARCEVA monotherapy is indicated for the treatment of patients
with locally advanced or metastatic non-small cell lung cancer after
failure of at least one prior chemotherapy regimen [see Clinical
Studies (<a href="#i4i_section_ID_18703A53-C4DA-4851-BB63-10CCC6F5FF3B">14.1</a>)].
</p>
<p>Results from two, multicenter, placebo-controlled, randomized,
Phase 3 trials conducted in first-line patients with locally advanced
or metastatic NSCLC showed no clinical benefit with the concurrent
administration of TARCEVA with platinum-based chemotherapy
[carboplatin and paclitaxel or gemcitabine and cisplatin] and its use
is not recommended in that setting [see Clinical Studies (<a href="#i4i_section_ID_3E38A3DC-0BDA-4CD6-BD08-651B2A3228F2">14.3</a>)].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>1.2  Pancreatic Cancer</h2>
<p class="First"></p>
<p>TARCEVA in combination with gemcitabine is indicated for the
first-line treatment of patients with locally advanced, unresectable
or metastatic pancreatic cancer [see Clinical Studies (<a href="#i4i_section_ID_4AC5E867-63E2-4F5E-9D2E-8842B157D1F8">14.3</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2.  DOSAGE AND ADMINISTRATION</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1  Recommended Dose - NSCLC</h2>
<p class="First"></p>
<p>The recommended daily dose of TARCEVA for non-small cell lung
cancer is 150 mg taken at least one hour before or two hours after
the ingestion of food. Treatment should continue until disease
progression or unacceptable toxicity occurs. There is no evidence
that treatment beyond progression is beneficial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2  Recommended Dose - Pancreatic Cancer</h2>
<p class="First"></p>
<p>The recommended daily dose of TARCEVA for pancreatic cancer is 100
mg taken at least one hour before or two hours after the ingestion of
food, in combination with gemcitabine (see the gemcitabine package
insert). Treatment should continue until disease progression or
unacceptable toxicity occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>2.3  Dose Modifications</h2>
<p class="First"></p>
<p>In patients who develop an acute onset of new or progressive
pulmonary symptoms, such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, treatment with
TARCEVA should be interrupted pending diagnostic evaluation. If
<span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> (ILD) is diagnosed, TARCEVA should be
discontinued and appropriate treatment instituted as necessaryÂ [see
Warnings and Precautions (<a href="#i4i_section_ID_7E2E1FA3-88F8-4942-9B3A-3DEF35EB2DCC">5.1</a>)].
</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> can usually be managed with loperamide. Patients with
severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> who are unresponsive to loperamide or who become
dehydrated may require dose reduction or temporary interruption of
therapy. Patients with severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may also require dose
reduction or temporary interruption of therapy.</p>
<p>When dose reduction is necessary, the TARCEVA dose should be
reduced in 50 mg decrements.</p>
<p>In patients who are taking TARCEVA with a strong CYP3A4 inhibitor
such as, but not limited to, atazanavir, clarithromycin, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir,
saquinavir, telithromycin, troleandomycin (TAO), voriconazole, or
grapefruit or grapefruit juice, a dose reduction should be considered
if severe adverse reactions occur. Similarly, in patients who are
taking TARCEVA with an inhibitor of both CYP3A4 and CYP1A2 like
ciprofloxacin, a dose reduction of TARCEVA should be considered if
severe adverse reactions occur. [see Drug Interactions (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)].
</p>
<p>Pre-treatment with the CYP3A4 inducer rifampicin decreased
erlotinib AUC by about 2/3 to 4/5. Use of alternative treatments
lacking CYP3A4 inducing activity is strongly recommended. If an
alternative treatment is unavailable, an increase in the dose of
TARCEVA should be considered as tolerated at two week intervals while
monitoring the patientâ€™s safety. The maximum dose of TARCEVA
studied in combination with rifampicin is 450 mg. If the TARCEVA dose
is adjusted upward, the dose will need to be reduced immediately to
the indicated starting dose upon discontinuation of rifampicin or
other inducers. Other CYP3A4 inducers include, but are not limited to
rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and
St. John's Wort. These too should be avoided if possibleÂ [see
Drug Interactions (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)].
</p>
<p>Cigarette smoking has been shown to reduce erlotinib
exposure.Â Patients should be advised to stop smoking. If a
patient continues to smoke, a cautious increase in the dose of
TARCEVA, not exceeding 300 mg may be considered, while monitoring the
patientâ€™s safety. However, efficacy and long-term safety (&gt; 14
days) of a dose higher than the recommended starting doses have not
been established in patients who continue to smoke cigarettes. If the
TARCEVA dose is adjusted upward, the dose should be reduced
immediately to the indicated starting dose upon cessation of
smokingÂ [see Clinical Pharmacology (<a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3</a>)].
</p>
<p>Erlotinib is eliminated by hepatic metabolism and biliary
excretion. Although erlotinib exposure was similar in patients with
moderately impaired hepatic function (Child-Pugh B), patients with
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt; ULN or Child-Pugh A, B and
C) should be closely monitored during therapy with TARCEVA [see
WARNINGS and PRECAUTIONS (<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2
</a>)]. Treatment with TARCEVA should be used with extra caution in
patients with total bilirubin &gt; 3 x ULN.Â Â  TARCEVA
dosing should be interrupted or discontinued if changes in liver
function are severe such as doubling of total bilirubin and/or
tripling of transaminases in the setting of pretreatment values
outside normal range. In the setting of worsening liver function
tests, before they become severe, dose interruption and/or dose
reduction with frequent liver function test monitoring should be
considered. TARCEVA dosing should be interrupted or discontinued if
total bilirubin is &gt;3 x ULN and/or transaminases are &gt;5 x ULN
in the setting of normal pretreatment values [see Warnings and
Precautions (<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2
</a>, <a href="#i4i_section_ID_B53F31A4-1715-47D7-A2E9-69CB5299C84D">5.3
</a>), Adverse Reactions (<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>)
and Use in Specific Populations (<a href="#i4i_section_ID_44A7760D-EC83-4C1E-B201-8D064F136C38">8.6
</a>)].Â  
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3.  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"></p>
<p>25 mg tablets</p>
<p>White film-coated tablets for daily oral administration. Round,
biconvex face and straight sides, white film-coated, printed in
orange with a â€œTâ€? and â€œ25â€? on one side and plain on the other
side.</p>
<p>100 mg tablets</p>
<p>White film-coated tablets for daily oral administration. Round,
biconvex face and straight sides, white film-coated, printed in gray
with â€œTâ€? and â€œ100â€? on one side and plain on the other side.</p>
<p>150 mg tablets</p>
<p>White film-coated tablets for daily oral administration. Round,
biconvex face and straight sides, white film-coated, printed in
maroon with â€œTâ€? and â€œ150â€? on one side and plain on the other
side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4.  CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5.  WARNINGS AND PRECAUTIONS</h1>
<p class="First">Enter section text here</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1  Pulmonary Toxicity</h2>
<p class="First"></p>
<p>There have been infrequent reports of serious Interstitial Lung
Disease (ILD)-like events, including fatalities, in patients
receiving TARCEVA for treatment of NSCLC, pancreatic cancer or other
advanced <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. In the randomized single-agent NSCLC study
[see CLINICAL STUDIES (<a href="#i4i_section_ID_18703A53-C4DA-4851-BB63-10CCC6F5FF3B">14.1</a>)],
the incidence of ILD-like events (0.8%) was the same in both the
placebo and TARCEVA groups. In the pancreatic cancer study - in
combination with gemcitabine â€“Â  [see Clinical Studies
(<a href="#i4i_section_ID_4AC5E867-63E2-4F5E-9D2E-8842B157D1F8">14.3</a>)],Â the
incidence of ILD-like events was 2.5% in the TARCEVA plus gemcitabine
group vs. 0.4% in the placebo plus gemcitabine group. 
</p>
<p>The overall incidence of ILD-like events in approximately 4900
TARCEVA-treated patients from all studies (including uncontrolled
studies and studies with concurrent chemotherapy) was approximately
0.7%. Reported diagnoses in patients suspected of having ILD-like
events included <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4221865" conceptname="Radiation pneumonitis">radiation pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>,
<span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">obliterative bronchiolitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, Acute Respiratory
Distress Syndrome and lung infiltration. Symptoms started from 5 days
to more than 9 months (median 39 days) after initiating TARCEVA
therapy. In the lung cancer trials most of the cases were associated
with confounding or contributing factors such as concomitant/prior
chemotherapy, prior radiotherapy, pre-existing parenchymal lung
disease, metastatic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, or pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. 
</p>
<p>In the event of an acute onset of new or progressive unexplained
pulmonary symptoms such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, TARCEVA therapy
should be interrupted pending diagnostic evaluation. If ILD is
diagnosed, TARCEVA should be discontinued and appropriate treatment
instituted as needed [see Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3
</a>)]. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"></p>
<p>In a pharmacokinetic study in patients with moderate hepatic
impairment (Child-Pugh B) associated with significant <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>
burden, 10 out of 15 patients died on treatment or within 30 days of
the last TARCEVA dose. One patient died from <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span>, 1
patient died from rapidly progressing <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and the remaining
8 patients died from progressive disease. Six out of the 10 patients
who died had baseline total bilirubin &gt; 3 x ULN suggesting severe
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Treatment with TARCEVA should be used with extra
caution in patients with total bilirubin &gt; 3 x ULN. Patients with
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt; ULN or Child-Pugh A, B and
C) should be closely monitored during therapy with TARCEVA. TARCEVA
dosing should be interrupted or discontinued if changes in liver
function are severe such as doubling of total bilirubin and/or
tripling of transaminases in the setting of pretreatment values
outside normal range [see Clinical Pharmacology (<a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3</a>)
and Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3
</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3  Hepatotoxicity</h2>
<p class="First"></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span> (including
fatalities) have been reported during use of TARCEVA, particularly in
patients with baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therefore, periodic liver
function testing (transaminases, bilirubin, and alkaline phosphatase)
is recommended. In the setting of worsening liver function tests,
dose interruption and/or dose reduction with frequent liver function
test monitoring should be considered. TARCEVA dosing should be
interrupted or discontinued if total bilirubin is &gt;3 x ULN and/or
transaminases are &gt;5 x ULN in the setting of normal pretreatment
values [see Adverse Reactions (<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>)
and Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3
</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First"></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (including
fatalities), and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have been reported. Some were
secondary to baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> while others were associated
with severe <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> or
concurrent chemotherapy use. In the event of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>,
particularly in patients with contributing risk factors for renal
failure (eg, pre-existing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, medical conditions or
medications that may lead to <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or other predisposing
conditions including advanced age), TARCEVA therapy should be
interrupted and appropriate measures should be taken to intensively
rehydrate the patient. Periodic monitoring of renal function and
serum electrolytes is recommended in patients at risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>
[see Adverse Reactions (<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>)
and Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3
</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span></h2>
<p class="First"></p>
<p>In the pancreatic carcinoma trial, six patients (incidence of
2.3%) in the TARCEVA/gemcitabine group developed myocardial
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. One of these patients died due to myocardial
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>. In comparison, 3 patients in the placebo/gemcitabine
group developed <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (incidence 1.2%) and one died
due to <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span></h2>
<p class="First"></p>
<p>In the pancreatic carcinoma trial, six patients in the
TARCEVA/gemcitabine group developed <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>
(incidence: 2.3%). One of these was hemorrhagic and was the only
fatal event. In comparison, in the placebo/gemcitabine group there
were no <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>5.7  <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">Microangiopathic Hemolytic Anemia</span> with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First"></p>
<p>In the pancreatic carcinoma trial, two patients in the
TARCEVA/gemcitabine group developed <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span>
with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (incidence: 0.8%). Both patients received
TARCEVA and gemcitabine concurrently. In comparison, in the
placebo/gemcitabine group there were no cases of microangiopathic
<span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>5.8  Use in Pregnancy</h2>
<p class="First"></p>
<p>Pregnancy Category D 
</p>
<p>Women of childbearing potential should avoid becoming pregnant
while being treated with TARCEVA. Erlotinib administered to rabbits
during organogenesis at doses that result in plasma drug
concentrations of approximately 3 times those in humans (AUCs at 150
mg daily dose) was associated with embryo/fetal lethality and
abortion. When erlotinib was administered to female rats prior to
mating and through the first week of pregnancy, at doses 0.3 or 0.7
times the clinical dose of 150 mg, on a mg/m2 basis, there was an
increase in early resorptions that resulted in a decrease in the
number of live fetuses. [see Use in Specific Populations (<a href="#i4i_section_ID_A7A7A645-64A9-4833-A93B-F3A4D894AAA9">8.1</a>)]
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>5.9  Elevated International Normalized Ratio and Potential <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First"></p>
<p>International Normalized Ratio (INR) elevations and infrequent
reports of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events including gastrointestinal and
non-<span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleedings</span> have been reported in clinical
studies, some associated with concomitant warfarin administration.
Patients taking warfarin or other coumarin-derivative anticoagulants
should be monitored regularly for changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or
INR.Â [see Adverse Reactions (<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>)].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6.  ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Because clinical trials are conducted under widely varying
conditions, adverse reactions rates observed in the clinical trials
of a drug cannot be directly compared to rates in the clinical trials
of another drug and may not reflect the rates observed in practice.</p>
<p>Safety evaluation of TARCEVA is based on 856 cancer patients who
received TARCEVA as monotherapy, 308 patients who received TARCEVA
100 or 150 mg plus gemcitabine, and 1228 patients who received
TARCEVA concurrently with other chemotherapies. 
</p>
<p>There have been reports of serious events, including fatalities,
in patients receiving TARCEVA for treatment of NSCLC, pancreatic
cancer or other advanced solid tumorsÂ [see Warnings and
Precautions (<a href="#i4i_warnings_precautions_ID_568ED0BC-9300-41EE-BBB2-A01AB0B5B726">5</a>)
and Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3
</a>)]. 
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Non-Small Cell Lung Cancer</h2>
<p class="First">Adverse events, regardless of causality, that occurred in at least 10% of patients treated with single-agent TARCEVA at 150 mg and at least 3% more often than in the placebo group in the randomized trial of patients with NSCLC are summarized by NCI-CTC (version 2.0) Grade in Table 1.</p>
<p>The most common adverse reactions in patients receiving single-agent TARCEVA 150 mg were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Grade 3/4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 9% and 6%, respectively, in TARCEVA-treated patients. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> each resulted in study discontinuation in 1% of TARCEVA-treated patients. Six percent and 1% of patients needed dose reduction for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, respectively. The median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 8 days, and the median time to onset of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 12 days.Â </p>
<a name="ID_DCE8BB6A-9C0B-4008-B0D0-93CABE6177AE"></a><table cellpadding="0" frame="box" width="350.000">
<caption><span>Table 1: Adverse Reactions Occurring More Frequently (â‰¥ 3%) in the Single Agent TARCEVA Group than in the Placebo Group and in â‰¥10% of Patients in the TARCEVA Group.</span></caption>
<col width="27.7%">
<col width="11.1%">
<col width="13.7%">
<col width="12.0%">
<col width="12.0%">
<col width="12.0%">
<col width="11.4%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom"><span class="Bold">TARCEVA 150 mg<br>N = 485</span></td>
<td class="Botrule" align="center" colspan="3" valign="bottom"><span class="Bold">Placebo<br>N = 242</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">NCI-CTC Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Any Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Any Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">MedDRAÂ PreferredÂ Term</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule" align="center" valign="top">75</td>
<td class="Botrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">17</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule" align="center" valign="top">54</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">18</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule" align="center" valign="top">52</td>
<td class="Botrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">38</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule" align="center" valign="top">52</td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule" align="center" valign="top">45</td>
<td class="Botrule" align="center" valign="top">16</td>
<td class="Botrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule" align="center" valign="top">41</td>
<td class="Botrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">35</td>
<td class="Botrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">11</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Botrule" align="center" valign="top">33</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">29</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule" align="center" valign="top">33</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">24</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule" align="center" valign="top">24</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="center" valign="top">23</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">19</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Botrule" align="center" valign="top">17</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Keratoconjunctivitis sicca</span></td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">7</td>
<td class="Botrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
</tbody>
</table>
<p>Liver function test abnormalities (including elevated <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) and bilirubin) were observed in patients receiving single-agent TARCEVA 150 mg. These elevations were mainly transient or associated with liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. Grade 2 (&gt;2.5 â€“ 5.0 x ULN) ALT elevations occurred in 4% and &lt;1% of TARCEVA and placebo treated patients, respectively. Grade 3 (&gt;5.0 â€“ 20.0 x ULN) elevations were not observed in TARCEVA-treated patients. TARCEVA dosing should be interrupted or discontinued if changes in liver function are severe.<span class="Italics"> [see <span class="Italics">Dosage and Administration</span> (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_BD77E135-98BC-4261-8ED6-4ACCF7196AD4"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Pancreatic Cancer</h2>
<p class="First">Adverse events, regardless of causality, that occurred in at least 10% of patients treated with TARCEVA 100 mg plus gemcitabine in the randomized trial of patients with pancreatic cancer are summarized by NCI-CTC (version 2.0) Grade in Table 2.</p>
<p>The most common adverse reactions in pancreatic cancer patients receiving TARCEVA 100 mg plus gemcitabine were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. In the TARCEVA plus gemcitabine arm, Grade 3/4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were each reported in 5% of TARCEVA plus gemcitabine-treated patients. The median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 10 days and 15 days, respectively. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> each resulted in dose reductions in 2% of patients, and resulted in study discontinuation in up to 1% of patients receiving TARCEVA plus gemcitabine. The 150 mg cohort was associated with a higher rate of certain class-specific adverse reactions including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and required more frequent dose reduction or interruption.Â </p>
<a name="ID_5C2C9CAC-BAF2-4BDA-921B-CBF738B4869C"></a><table border="single" cellpadding="0" frame="box" width="351.000">
<caption><span>Table 2: Adverse Reactions Occurring in â‰¥ 10% of TARCEVA-treated Pancreatic Cancer Patients: 100 mg cohort</span></caption>
<col width="27.6%">
<col width="13.1%">
<col width="12.0%">
<col width="12.0%">
<col width="11.7%">
<col width="11.7%">
<col width="12.0%">
<tfoot><tr class="Last"><td class="Botrule" align="left" colspan="7" valign="top">*Includes all MedDRA preferred terms in the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> System Organ Class</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom"><span class="Bold">TARCEVA + Gemcitabine<br>1000Â mg/m<span class="Sup">2</span> IV<br>N=259</span></td>
<td class="Botrule" align="center" colspan="3" valign="bottom"><span class="Bold">Placebo + Gemcitabine <br>1000Â mg/m<span class="Sup">2</span> IV<br>N=256</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">NCI-CTC Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Any Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Any Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">MedDRAÂ PreferredÂ Term</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">%</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">%</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule" align="center" valign="top">73</td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">70</td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule" align="center" valign="top">69</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">30</td>
<td class="Botrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule" align="center" valign="top">60</td>
<td class="Botrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">58</td>
<td class="Botrule" align="center" valign="top">7</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule" align="center" valign="top">52</td>
<td class="Botrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">52</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule" align="center" valign="top">48</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">36</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule" align="center" valign="top">46</td>
<td class="Botrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">45</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule" align="center" valign="top">42</td>
<td class="Botrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">41</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule" align="center" valign="top">39</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">29</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>*</td>
<td class="Botrule" align="center" valign="top">39</td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">30</td>
<td class="Botrule" align="center" valign="top">9</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Botrule" align="center" valign="top">37</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">36</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Botrule" align="center" valign="top">36</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">30</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule" align="center" valign="top">31</td>
<td class="Botrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">34</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td class="Botrule" align="center" valign="top">25</td>
<td class="Botrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">23</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Botrule" align="center" valign="top">24</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">23</td>
<td class="Botrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Botrule" align="center" valign="top">22</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule" align="center" valign="top">21</td>
<td class="Botrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">20</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Botrule" align="center" valign="top">19</td>
<td class="Botrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule" align="center" valign="top">17</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Botrule" align="center" valign="top">16</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">16</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">1</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">10</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Botrule" align="center" valign="top">13</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">9</td>
<td class="Botrule" align="center" valign="top">&lt;1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Botrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Rrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">9</td>
<td class="Botrule" align="center" valign="top">0</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>In the pancreatic carcinoma trial, 10 patients in the TARCEVA/gemcitabine group developed deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (incidence: 3.9%). In comparison, 3 patients in the placebo/gemcitabine group developed deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (incidence 1.2%). The overall incidence of grade 3 or 4 thrombotic events, including deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, was similar in the two treatment arms: 11% for TARCEVA plus gemcitabine and 9% for placebo plus gemcitabine.</p>
<p>No differences in Grade 3 or Grade 4 hematologic laboratory toxicities were detected between the TARCEVA plus gemcitabine group compared to the placebo plus gemcitabine group.</p>
<p>Severe adverse events (â‰¥grade 3 NCI-CTC) in the TARCEVA plus gemcitabine group with incidences &lt; 5% included <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> including <span class="product-label-link" type="condition" conceptid="4198102" conceptname="Microangiopathic hemolytic anemia">microangiopathic hemolytic anemia</span> with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> including <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_ID_568ED0BC-9300-41EE-BBB2-A01AB0B5B726">5</a>)]. </span></p>
<p>Liver function test abnormalities (including elevated <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) and bilirubin) have been observed following the administration of TARCEVA plus gemcitabine in patients with pancreatic cancer. Table 3 displays the most severe NCI-CTC grade of liver function abnormalities that developed. TARCEVA dosing should be interrupted or discontinued if changes in liver function are severe <span class="Italics">[see <span class="Italics">Dosage and Administration</span> (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3</a>)].</span></p>
<a name="ID_F3A6EB16-8A1A-499D-AB91-090016FD65B0"></a><table border="single" cellpadding="0" frame="box" width="383.000">
<caption><span>Table 3: Liver Function Test Abnormalities (most severe NCI-CTC grade) in Pancreatic Cancer Patients: 100 mg Cohort</span></caption>
<col width="16.2%">
<col width="16.4%">
<col width="13.3%">
<col width="14.1%">
<col width="12.5%">
<col width="12.5%">
<col width="14.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="bottom"><span class="Bold">TARCEVA + Gemcitabine 1000 mg/m<span class="Sup">2</span> IV<br>N = 259</span></td>
<td class="Botrule" align="center" colspan="3" valign="bottom"><span class="Bold">Placebo + Gemcitabine 1000 mg/m<span class="Sup">2</span> IV<br>N = 256</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">NCI-CTC Grade</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 2</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 2</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 3</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Grade 4</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Bilirubin</td>
<td class="Botrule" align="center" valign="top">17 %</td>
<td class="Botrule" align="center" valign="top">10%</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1%</td>
<td class="Botrule" align="center" valign="top">11%</td>
<td class="Botrule" align="center" valign="top">10%</td>
<td class="Botrule" align="center" valign="top">3%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">ALT</td>
<td class="Botrule" align="center" valign="top">31% </td>
<td class="Botrule" align="center" valign="top">13%</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1%</td>
<td class="Botrule" align="center" valign="top">22%</td>
<td class="Botrule" align="center" valign="top">9%</td>
<td class="Botrule" align="center" valign="top">0%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">AST</td>
<td align="center" valign="top">24%</td>
<td class="Botrule" align="center" valign="top">10%</td>
<td class="Rrule" align="center" valign="top">&lt;1%</td>
<td class="Botrule" align="center" valign="top">19%</td>
<td class="Botrule" align="center" valign="top">9%</td>
<td class="Botrule" align="center" valign="top">0%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93"></a><a name="section-6.3"></a><p></p>
<h2>6.3 NSCLC and Pancreatic Cancer Indications</h2>
<p class="First">During the NSCLC and the combination pancreatic cancer trials, infrequent cases of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have been reported, some associated with concomitant warfarin or NSAID administration<span class="Italics">. [see Warnings and Precautions (<a href="#i4i_section_ID_014DBB7E-1FB4-4AAE-AB59-E54A206507AB">5.9</a>)].</span> These adverse events were reported as <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcers</span>), <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> from possible <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including fatalities, with or without <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> have been reported. <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_A7441A21-B523-48FB-B03D-6A185C3D982A">5.4</a>)].Â </span> Cases of Grade 1 <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> were also reported in both the single-agent NSCLC and the pancreatic cancer clinical trials.</p>
<p>NCI-CTC Grade 3 <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> have been reported infrequently in patients receiving TARCEVA therapy in the NSCLC and pancreatic cancer clinical trials. <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">Corneal ulcerations</span> may also occur. [<span class="Italics">see Patient Counseling Information (<a href="#i4i_info_patients_ID_9ED4E48C-1645-4CC2-ACD0-3F244E11D179">17</a>)].</span></p>
<p>Â Hair and <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span> including <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, eyelash/eyebrow changes, <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span> and brittle and loose nails have been reported in clinical trials and during post-marketing use of TARCEVA.</p>
<p>In patients who develop <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, the appearance of the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is typically erythematous and maculopapular and it may resemble <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> with follicular <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, but is histopathologically different.  This <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> commonly occurs on the face, upper chest and back, but may be more generalized or severe (NCI-CTC Grade 3 or 4) with <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>.  Associated symptoms may include <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and/or burning.  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span> with or without digital <span class="product-label-link" type="condition" conceptid="4083789" conceptname="Chapped skin">skin fissures</span> may occur.  </p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> has been reported in patients treated with single-agent TARCEVA or TARCEVA combined with chemotherapy in clinical studies and during post-marketing use of TARCEVA <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_B53F31A4-1715-47D7-A2E9-69CB5299C84D">5.3 </a>)]; </span>it is not possible to reliably estimate the frequency or establish a causal relationship to TARCEVA treatment.</p>
<p>In general, no notable differences in the safety of TARCEVA monotherapy or in combination with gemcitabine could be discerned between females or males and between patients younger or older than the age of 65 years [<span class="Italics">s</span><span class="Italics">ee Use in Specific Populations (<a href="#i4i_section_ID_5715E335-49C9-4032-9992-92FECBB74058">8.4</a>)]</span>. The safety of TARCEVA appears similar in Caucasian and Asian patients<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<p class="First">Erlotinib is metabolized predominantly by CYP3A4, and inhibitors of CYP3A4 would be expected to increase exposure. Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3. When TARCEVA was co-administered with ciprofloxacin, an inhibitor of both CYP3A4 and CYP1A2, the erlotinib exposure [AUC] and maximum concentration [C<span class="Sub">max</span>] increased by 39% and 17% respectively. Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole and grapefruit or grapefruit juice. <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)]</span>.</p>
<p>Pre-treatment with the CYP3A4 inducer rifampicin for 7 days prior to TARCEVA decreased erlotinib AUC by about 2/3 to 4/5, which is equivalent to a dose of about 30 to 50 mg in NSCLC patients. In a separate study, treatment with rifampicin for 11 days, with co-administration of a single 450 mg dose of TARCEVA on day 8 resulted in a mean erlotinib exposure (AUC) that was 57.6% of that observed following a single 150 mg TARCEVA dose in the absence of rifampicin treatment  <span class="Italics">[see Dose Modifications (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)]</span>.Â Use of alternative treatments lacking CYP3A4 inducing activity is strongly recommended. If an alternative treatment is unavailable, adjusting the starting dose should be considered.   If the TARCEVA dose is adjusted upward, the dose will need to be reduced immediately to the indicated starting dose upon discontinuation of rifampicin or other inducers. Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. John's Wort <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)].</span></p>
<p>Cigarette smoking has been shown to reduce erlotinib AUC.  Patients should be advised to stop smoking; however, if they continue to smoke, a cautious increase in the dose of TARCEVA may be considered, while monitoring the patientâ€™s safety.  If the TARCEVA dose is adjusted upward, the dose should be reduced immediately to the indicated starting dose upon <span class="product-label-link" type="condition" conceptid="4310250" conceptname="Ex-smoker">cessation of smoking</span>. <span class="Italics">[see Dosage and Administration(<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>) and Clinical Pharmacology(<a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3</a>)].</span></p>
<p>Pretreatment and co-administration of TARCEVA decreased the AUC of CYP3A4 substrate, midazolam, by 24%. The mechanism is not clear.</p>
<p>In a study, there were no significant effects of gemcitabine on the pharmacokinetics of erlotinib nor were there significant effects of erlotinib on the pharmacokinetics of gemcitabine.</p>
<p>Drugs that alter the pH of the upper GI tract may alter the solubility of erlotinib and reduce its bioavailability. Co-administration of TARCEVA with omeprazole, a proton pump inhibitor, decreased the erlotinib AUC by 46%.  Increasing the dose of TARCEVA when co-administered with such agents is not likely to compensate for the loss of exposure. Since proton pump inhibitors affect pH of the upper GI tract for an extended period, separation of doses may not eliminate the interaction. The concomitant use of proton pump inhibitors with TARCEVA should be avoided if possible.   The use of antacids may be considered in place of histamine 2 receptor blockers (H<span class="Sub">2</span> blockers) or proton pump inhibitors in patients receiving TARCEVA. However, no clinical study has been conducted to evaluate the effect of antacids on erlotinib pharmacokinetics. If an antacid is necessary, the antacid dose and the TARCEVA dose should be separated by several hours [<span class="Italics">seeÂ Clinical Pharmacology (<span class="Italics"><a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3</a></span>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_4CADE36D-6E10-4257-8713-A7F7CA84840C"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A7A7A645-64A9-4833-A93B-F3A4D894AAA9"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D [See <span class="Italics">Warnings and Precautions (<a href="#i4i_section_ID_D2F3C49F-56A4-4CB0-86A0-0B1740C09D6B">5.8</a>)</span>]</p>
<p>Erlotinib has been shown to cause maternal toxicity with associated embryo/fetal lethality and abortion in rabbits when given at doses that result in plasma drug concentrations of approximately 3 times those in humans (AUCs at 150 mg daily dose). When given during the period of organogenesis to achieve plasma drug concentrations approximately equal to those in humans, based on AUC, there was no increased incidence of embryo/fetal lethality or abortion in rabbits or rats. However, female rats treated with 30 mg/m<span class="Sup">2</span>/day or 60 mg/m<span class="Sup">2</span>/day (0.3 or 0.7 times the clinical dose, on a mg/m<span class="Sup">2</span> basis) of erlotinib prior to mating through the first week of pregnancy had an increase in early resorptions that resulted in a decrease in the number of live fetuses.</p>
<p>No teratogenic effects were observed in rabbits or rats dosed with erlotinib during organogenesis at doses up to 600 mg/m<span class="Sup">2</span>/day in the rabbit (3 times the plasma drug concentration seen in humans at 150 mg/day) and up to 60 mg/m<span class="Sup">2</span>/day in the rat (0.7 times the clinical dose of 150 mg/day on a mg/m<span class="Sup">2</span> basis).</p>
<p>There are no adequate and well-controlled studies in pregnant women using TARCEVA. Women of childbearing potential should be advised to avoid pregnancy while on TARCEVA. Adequate contraceptive methods should be used during therapy, and for at least 2 weeks after completing therapy. Treatment should only be continued in pregnant women if the potential benefit to the mother outweighs the risk to the fetus. If TARCEVA is used during pregnancy, the patient should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy <span class="Italics">[see Warnings and Precautions <span class="Italics">(<a href="#i4i_section_ID_D2F3C49F-56A4-4CB0-86A0-0B1740C09D6B">5.8</a>)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3351D91B-6F3E-4AB7-B3E3-F1013A8702C7"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether erlotinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TARCEVA, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_5715E335-49C9-4032-9992-92FECBB74058"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of TARCEVA in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_AB61F3EB-8F68-42D4-8DE6-9E8B2FEA7582"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients participating in the randomized NSCLC trial, 62% were less than 65 years of age, and 38% of patients were aged 65 years or older. The survival benefit was maintained across both age groups [HR = 0.75 (95% CI: 0.6, 0.9) in patients less than 65 years of age, and HR = 0.79 (95% CI: 0.6, 1.0) in patients who were 65 years or older]<span class="Italics">.</span></p>
<p>In the pancreatic cancer study, 53% of patients were younger than 65 years of age and 47% were 65 years of age or older. There were no clinically relevant differences between the age groups [HR = 0.78 (95% CI: 0.6, 1.0) in patients less than 65 years of age, and HR = 0.94 (95% CI: 0.7, 1.2) in patients who were 65 years or older]. No meaningful differences in safety or pharmacokinetics were observed between younger and older patients in either study. Therefore, no dosage adjustments are recommended in elderly patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_44A7760D-EC83-4C1E-B201-8D064F136C38"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Gender </h2>
<p class="First">Of the total number of patients participating in the randomized NSCLC trial, 65% were males and 35% females.  There were no clinically relevant differences in safety and efficacy based on gender [HR = 0.76 (95% CI: 0.6, 0.9) in males and HR = 0.80 (95% CI: 0.6, 1.1) in females].</p>
<p>In the pancreatic cancer study, 52% of patients were males and 48% females. There were no clinically relevant differences in safety and efficacy based on gender [HR = 0.74 (95% CI: 0.6, 0.9) in males and HR = 1.0 (95% CI: 0.8, 1.3) in females].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F994F09C-3413-44AE-9D3A-547A16E066B2"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Race</h2>
<p class="First">In the randomized NSCLC trial, 78% of all patients were Caucasian and 12% were Asian.   There were no clinically relevant differences in safety and efficacy based on race [HR = 0.79 (95% CI: 0.6, 1.0) in Caucasians and HR = 0.61 (95% CI: 0.4, 1.0) in Asians].</p>
<p>In the pancreatic cancer study, 88% of all patients were Caucasian and 7% were Asian.   There were no clinically relevant differences in safety and efficacy based on race [HR = 0.88 (95% CI: 0.7, 1.1) in Caucasians and HR = 0.61 (95% CI: 0.3, 1.3) in Asians].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_23E094D3-C471-4995-9169-D948685D3115"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt; ULN or Child Pugh A, B and C) should be closely monitored during therapy with TARCEVA.  Treatment with TARCEVA should be used with extra caution in patients with total bilirubin &gt; 3 x ULN [<span class="Italics">see Warnings <span class="Italics">(<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2 </a></span>), Adverse Reactions <span class="Italics">(<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>)</span>, and Dosage and Administration <span class="Italics">(<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)</span>]</span>.</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> evidence suggest that erlotinib is cleared primarily by the liver. However, erlotinib exposure was similar in patients with moderately impaired hepatic function (Child-Pugh B) compared with patients with adequate hepatic function including patients with primary liver cancer or hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> <span class="Italics">[see Dosage and Administration <span class="Italics">(<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)</span> and Clinical Pharmacology <span class="Italics"> (<a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3</a>)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_0E349CC8-BEF4-4EDE-A789-5BB7F8362315"></a><a name="section-8.8"></a><p></p>
<h2>8.9 Patients with Renal ImpairmentÂ </h2>
<p class="First">Less than 9% of a single dose is excreted in the urine. No clinical studies have been conducted in patients with compromised renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_4420B502-F5F7-485B-B522-1DB90C142493"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">Single oral doses of TARCEVA up to 1,000 mg in healthy subjects and weekly doses up to 1,600 mg in cancer patients have been tolerated. Repeated twice-daily doses of 200 mg single-agent TARCEVA in healthy subjects were poorly tolerated after only a few days of dosing. Based on the data from these studies, an unacceptable incidence of severe adverse events, such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and liver transaminase elevation, may occur above the recommended dose <span class="Italics">[see Dosage and Administration (<a href="#i4i_dosage_admin_ID_E0A139A0-E769-4DC6-907E-875E88A5183F">2</a>)].</span> In case of suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, TARCEVA should be withheld and symptomatic treatment instituted.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_B2C835E2-65B2-4B16-9762-EFE532CB0870"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">TARCEVA (erlotinib), a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. TARCEVA contains erlotinib as the hydrochloride salt that has the following structural formula:</p>
<p><img alt="image of chemical formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=tarceva-01.jpg"></p>
<p>Erlotinib hydrochloride has the molecular formula C<span class="Sub">22</span>H<span class="Sub">23</span>N<span class="Sub">3</span>O<span class="Sub">4</span>.HCl and a molecular weight of 429.90. The molecule has a pK<span class="Sub">a</span> of 5.42 at 25<span class="Sup">o</span>C. Erlotinib hydrochloride is very slightly soluble in water, slightly soluble in methanol and practically insoluble in acetonitrile, acetone, ethyl acetate and hexane.</p>
<p>Aqueous solubility of erlotinib hydrochloride is dependent on pH with increased solubility at a pH of less than 5 due to protonation of the secondary amine. Over the pH range of 1.4 to 9.6, maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2.</p>
<p>TARCEVA tablets for oral administration are available in three dosage strengths containing erlotinib hydrochloride (27.3 mg, 109.3 mg and 163.9 mg) equivalent to 25 mg, 100 mg and 150 mg erlotinib and the following inactive ingredients: lactose monohydrate, hypromellose, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate and titanium dioxide. The tablets also contain trace amounts of color additives, including FD&amp;C Yellow #6 (25 mg only) for product identification.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_503CD74A-E7FF-4391-AC2C-B2041F79D30F"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_duplicate_ID_B2CF53C4-AB76-440B-87CE-365F39981950"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of clinical antitumor action of erlotinib is not fully characterized.   Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption and Distribution:</span></p>
<p>Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.  Peak plasma levels occur 4 hours after dosing.  The solubility of erlotinib is pH dependent.  Erlotinib solubility decreases as pH increases.  Co-administration of TARCEVA with omeprazole, a proton pump inhibitor, decreased the erlotinib exposure [AUC] and maximum concentration [C<span class="Sub">max</span>] by 46% and 61% respectively <span class="Italics">[see Drug Interactions (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>)]</span>.</p>
<p>Following absorption, erlotinib is approximately 93% protein bound to plasma albumin and alpha-1 acid glycoprotein (AAG). Erlotinib has an apparent volume of distribution of 232 liters.</p>
<p><span class="Bold">Metabolism and Excretion:</span></p>
<p>A population pharmacokinetic analysis in 591 patients receiving single-agent TARCEVA showed a median half-life of 36.2 hours. Time to reach steady state plasma concentration would therefore be 7 â€“ 8 days. No significant relationships of clearance to covariates of patient age, body weight or gender were observed. Smokers had a 24% higher rate of erlotinib clearance. </p>
<p>A second population pharmacokinetic analysis was conducted that incorporated erlotinib data from 204 pancreatic cancer patients who received erlotinib plus gemcitabine. This analysis demonstrated that covariates affecting erlotinib clearance in patients from the pancreatic study were very similar to those seen in the prior single-agent pharmacokinetic analysis. No new covariate effects were identified. Co-administration of gemcitabine had no effect on erlotinib plasma clearance.</p>
<p><span class="Italics">In vitro</span> assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1. Following a 100 mg oral dose, 91% of the dose was recovered: 83% in feces (1% of the dose as intact parent) and 8% in urine (0.3% of the dose as intact parent). </p>
<p>Cigarette smoking reduces erlotinib exposure. In the Phase 3 NSCLC trial, current smokers achieved erlotinib steady-state trough plasma concentrations which was approximately 2-fold less than the former smokers or patients who had never smoked. This effect was accompanied by a 24% increase in apparent erlotinib plasma clearance.  In a separate study which evaluated the single-dose pharmacokinetics of erlotinib in healthy volunteers, current smokers cleared the drug faster than former smokers or volunteers who had never smoked.  The AUC<span class="Sub">0-infinity</span> in smokers was about 1/3 to 1/2 of that in never/former smokers.  In another study which was conducted in NSCLC patients (N=35) who were current smokers, pharmacokinetic analyses at steady-state indicated a dose-proportional increase in erlotinib exposure when the TARCEVA dose was increased from 150 mg to 300 mg.  However, the exact dose to be recommended for patients who currently smoke is unknown <span class="Italics">[see Drug Interactions (<a href="#i4i_interactions_ID_18C0A33C-422D-487C-959A-E89F830CD495">7</a>) and Patient Counseling Information (<a href="#i4i_info_patients_ID_9ED4E48C-1645-4CC2-ACD0-3F244E11D179">17</a>)].Â </span>Â </p>
<p><span class="Italics">Special Populations:</span></p>
<p><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (total bilirubin &gt; ULN or Child Pugh A, B and C) should be closely monitored during therapy with TARCEVA.  Treatment with TARCEVA should be used with extra caution in patients with total bilirubin &gt; 3 x ULN <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_AFFB9BBA-E477-460C-AA1E-1B9C80496594">5.2 </a>), Adverse Reactions (<a href="#i4i_section_ID_9A0E181E-5091-4A48-A98A-3AC37BEEDC93">6.3</a>), and Dosage and Administration <span class="Italics">(<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3 </a>)</span>]</span>.</p>
<p><span class="Italics">In vitro </span>and <span class="Italics">in vivo </span>evidence suggest that erlotinib is cleared primarily by the liver. However, erlotinib exposure was similar in patients with moderately impaired hepatic function (Child-Pugh B) compared with patients with adequate hepatic function including patients with primary liver cancer or hepatic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.</p>
<p><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>Â </p>
<p>Less than 9% of a single dose is excreted in the urine. No clinical studies have been conducted in patients with compromised renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_ID_C098B8D0-4B3C-41CE-916E-25A821124785"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_section_ID_08E08951-2E77-4AB7-A55A-4E8C36ACAE37"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Erlotinib has not been tested for carcinogenicity.</p>
<p>Erlotinib has been tested for genotoxicity in a series of <span class="Italics">in vitro</span>Â  assays (bacterial mutation, human lymphocyte chromosome aberration, and mammalian cell mutation) and an <span class="Italics">in vivo </span>mouse bone marrow micronucleus test and did not cause genetic damage. </p>
<p>Erlotinib did not impair fertility in either male or female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_B07EC556-7BA6-4E1C-AE76-757290974F0C"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_18703A53-C4DA-4851-BB63-10CCC6F5FF3B"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Non-Small Cell Lung Cancer NSCLC â€“ TARCEVA Administered as a Single Agent</h2>
<p class="First">The efficacy and safety of single-agent TARCEVA was assessed in a randomized, double blind, placebo-controlled trial in 731 patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen. Patients were randomized 2:1 to receive TARCEVA 150Â mg or placebo (488 Tarceva, 243 placebo) orally once daily until disease progression or unacceptable toxicity. Study endpoints included overall survival, response rate, and progression-free survival (PFS). Duration of response was also examined. The primary endpoint was survival. The study was conducted in 17 countries. </p>
<p>Table 4 summarizes the demographic and disease characteristics of the study population. Demographic characteristics were well balanced between the two treatment groups. About two-thirds of the patients were male. Approximately one-fourth had a baseline ECOG performance status (PS) of 2, and 9% had a baseline ECOG PS of 3. Fifty percent of the patients had received only one prior regimen of chemotherapy. About three quarters of these patients were known to have smoked at some time.</p>
<a name="ID_E79B49B5-FA0A-498B-9281-588AC1146FAD"></a><table border="single" width="340.000">
<caption><span>Table 4: Demographic and Disease Characteristics</span></caption>
<col width="42.1%">
<col width="14.1%">
<col width="14.1%">
<col width="14.1%">
<col width="15.6%">
<tfoot><tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">* Stratification factor as documented at baseline; distribution differs slightly from values reported at time of randomization.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top"><span class="Bold">TARCEVA<br>(N = 488)</span></td>
<td class="Botrule" align="center" colspan="2" valign="top"><span class="Bold">Placebo<br>(N = 243)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Characteristics</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">n</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">(%)</span></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Gender</span></td>
<td class="Rrule" align="right" valign="top"></td>
<td class="Rrule" align="right" valign="top"></td>
<td class="Rrule" align="right" valign="top"></td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Female</td>
<td class="Rrule" align="center" valign="top">173</td>
<td class="Rrule" align="center" valign="top">(35)</td>
<td class="Rrule" align="center" valign="top">83</td>
<td align="center" valign="top">(34)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Male</td>
<td class="Botrule Rrule" align="center" valign="top">315</td>
<td class="Botrule Rrule" align="center" valign="top">(65)</td>
<td class="Botrule Rrule" align="center" valign="top">160</td>
<td class="Botrule" align="center" valign="top">(66)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Age (years)</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â &lt; 65</td>
<td class="Rrule" align="center" valign="top">299</td>
<td class="Rrule" align="center" valign="top">(61)</td>
<td class="Rrule" align="center" valign="top">153</td>
<td align="center" valign="top">(63)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">     â‰¥ 65</td>
<td class="Botrule Rrule" align="center" valign="top">189</td>
<td class="Botrule Rrule" align="center" valign="top">(39)</td>
<td class="Botrule Rrule" align="center" valign="top">90</td>
<td class="Botrule" align="center" valign="top">(37)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Race</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Caucasian</td>
<td class="Rrule" align="center" valign="top">379</td>
<td class="Rrule" align="center" valign="top">(78)</td>
<td class="Rrule" align="center" valign="top">188</td>
<td align="center" valign="top">(77)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Black</td>
<td class="Rrule" align="center" valign="top">18</td>
<td class="Rrule" align="center" valign="top">(4)</td>
<td class="Rrule" align="center" valign="top">12</td>
<td align="center" valign="top">(5)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Asian</td>
<td class="Rrule" align="center" valign="top">63</td>
<td class="Rrule" align="center" valign="top">(13)</td>
<td class="Rrule" align="center" valign="top">28</td>
<td align="center" valign="top">(12)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Other</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
<td class="Botrule Rrule" align="center" valign="top">(6)</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule" align="center" valign="top">(6)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">ECOG Performance Status at Baseline*</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 0</td>
<td class="Rrule" align="center" valign="top">64</td>
<td class="Rrule" align="center" valign="top">(13)</td>
<td class="Rrule" align="center" valign="top">34</td>
<td align="center" valign="top">(14)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 1</td>
<td class="Rrule" align="center" valign="top">256</td>
<td class="Rrule" align="center" valign="top">(52)</td>
<td class="Rrule" align="center" valign="top">132</td>
<td align="center" valign="top">(54)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 2</td>
<td class="Rrule" align="center" valign="top">126</td>
<td class="Rrule" align="center" valign="top">(26)</td>
<td class="Rrule" align="center" valign="top">56</td>
<td align="center" valign="top">(23)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â 3</td>
<td class="Botrule Rrule" align="center" valign="top">42</td>
<td class="Botrule Rrule" align="center" valign="top">(9)</td>
<td class="Botrule Rrule" align="center" valign="top">21</td>
<td class="Botrule" align="center" valign="top">(9)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span> in Previous 6 Months</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â &lt; 5%</td>
<td class="Rrule" align="center" valign="top">320</td>
<td class="Rrule" align="center" valign="top">(66)</td>
<td class="Rrule" align="center" valign="top">166</td>
<td align="center" valign="top">(68)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 5 â€“ 10%</td>
<td class="Rrule" align="center" valign="top">96</td>
<td class="Rrule" align="center" valign="top">(20)</td>
<td class="Rrule" align="center" valign="top">36</td>
<td align="center" valign="top">(15)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â &gt; 10%</td>
<td class="Rrule" align="center" valign="top">52</td>
<td class="Rrule" align="center" valign="top">(11)</td>
<td class="Rrule" align="center" valign="top">29</td>
<td align="center" valign="top">(12)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Unknown</td>
<td class="Botrule Rrule" align="center" valign="top">20</td>
<td class="Botrule Rrule" align="center" valign="top">(4)</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule" align="center" valign="top">(5)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Smoking History</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Never Smoked</td>
<td class="Rrule" align="center" valign="top">104</td>
<td class="Rrule" align="center" valign="top">(21)</td>
<td class="Rrule" align="center" valign="top">42</td>
<td align="center" valign="top">(17)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Current or Ex-smoker</td>
<td class="Rrule" align="center" valign="top">358</td>
<td class="Rrule" align="center" valign="top">(73)</td>
<td class="Rrule" align="center" valign="top">187</td>
<td align="center" valign="top">(77)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Unknown</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
<td class="Botrule Rrule" align="center" valign="top">(5)</td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">(6)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Histological Classification</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Adenocarcinoma</td>
<td class="Rrule" align="center" valign="top">246</td>
<td class="Rrule" align="center" valign="top">(50)</td>
<td class="Rrule" align="center" valign="top">119</td>
<td align="center" valign="top">(49)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Squamous</td>
<td class="Rrule" align="center" valign="top">144</td>
<td class="Rrule" align="center" valign="top">(30)</td>
<td class="Rrule" align="center" valign="top">78</td>
<td align="center" valign="top">(32)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Undifferentiated Large Cell</td>
<td class="Rrule" align="center" valign="top">41</td>
<td class="Rrule" align="center" valign="top">(8)</td>
<td class="Rrule" align="center" valign="top">23</td>
<td align="center" valign="top">(9)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Mixed Non-Small Cell</td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">(2)</td>
<td class="Rrule" align="center" valign="top">2</td>
<td align="center" valign="top">(&lt;1)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Other</td>
<td class="Botrule Rrule" align="center" valign="top">46</td>
<td class="Botrule Rrule" align="center" valign="top">(9)</td>
<td class="Botrule Rrule" align="center" valign="top">21</td>
<td class="Botrule" align="center" valign="top">(9)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Time from Initial Diagnosis to Randomization (Months)</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â &lt; 6</td>
<td class="Rrule" align="center" valign="top">63</td>
<td class="Rrule" align="center" valign="top">(13)</td>
<td class="Rrule" align="center" valign="top">34</td>
<td align="center" valign="top">(14)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 6 â€“ 12</td>
<td class="Rrule" align="center" valign="top">157</td>
<td class="Rrule" align="center" valign="top">(32)</td>
<td class="Rrule" align="center" valign="top">85</td>
<td align="center" valign="top">(35)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â &gt; 12</td>
<td class="Botrule Rrule" align="center" valign="top">268</td>
<td class="Botrule Rrule" align="center" valign="top">(55)</td>
<td class="Botrule Rrule" align="center" valign="top">124</td>
<td class="Botrule" align="center" valign="top">(51)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Best Response to Prior Therapy at Baseline*</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â CR/PR</td>
<td class="Rrule" align="center" valign="top">196</td>
<td class="Rrule" align="center" valign="top">(40)</td>
<td class="Rrule" align="center" valign="top">96</td>
<td align="center" valign="top">(40)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â PD</td>
<td class="Rrule" align="center" valign="top">101</td>
<td class="Rrule" align="center" valign="top">(21)</td>
<td class="Rrule" align="center" valign="top">51</td>
<td align="center" valign="top">(21)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â SD</td>
<td class="Botrule Rrule" align="center" valign="top">191</td>
<td class="Botrule Rrule" align="center" valign="top">(39)</td>
<td class="Botrule Rrule" align="center" valign="top">96</td>
<td class="Botrule" align="center" valign="top">(40)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Number of Prior Regimens at Baseline*</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 1</td>
<td class="Rrule" align="center" valign="top">243</td>
<td class="Rrule" align="center" valign="top">(50)</td>
<td class="Rrule" align="center" valign="top">121</td>
<td align="center" valign="top">(50)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â 2</td>
<td class="Rrule" align="center" valign="top">238</td>
<td class="Rrule" align="center" valign="top">(49)</td>
<td class="Rrule" align="center" valign="top">119</td>
<td align="center" valign="top">(49)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â 3</td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">(1)</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">(1)</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Bold">Exposure to Prior Platinum at Baseline*</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Â Â Â Â Â Yes</td>
<td class="Rrule" align="center" valign="top">454</td>
<td class="Rrule" align="center" valign="top">(93)</td>
<td class="Rrule" align="center" valign="top">224</td>
<td align="center" valign="top">(92)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Â Â Â Â Â No</td>
<td class="Rrule" align="center" valign="top">34</td>
<td class="Rrule" align="center" valign="top">(7)</td>
<td class="Rrule" align="center" valign="top">19</td>
<td class="Botrule" align="center" valign="top">(8)</td>
</tr>
</tbody>
</table>
<p>The results of the study are shown in Table 5.</p>
<br><a name="ID_16C1ACE9-405A-4035-8286-5E76C6B499E0"></a><table border="single" cellpadding="0" frame="box" width="350.000">
<caption><span>Table 5: Efficacy Results</span></caption>
<col width="20.3%">
<col width="17.1%">
<col width="13.7%">
<col width="13.7%">
<col width="15.1%">
<col width="20.0%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Two-sided Log-Rank test stratified by ECOG performance status, number of prior regimens, prior platinum, best response to prior chemotherapy.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold"> TARCEVA</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Hazard<br>Ratio ()</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">95%Â CI</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">p-value</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom">Survival</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"> Median</p>6.7 mo</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Median</p>4.7 mo</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.73</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.61 â€“ 0.86</td>
<td class="Botrule" align="center" valign="bottom">&lt;0.001 (<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom">1-year Survival</td>
<td class="Botrule Rrule" align="center" valign="bottom">31.2%</td>
<td class="Botrule Rrule" align="center" valign="bottom">21.5%</td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom">Progression-Free Survival</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"> Median</p>9.9 wk</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">Median</p>7.9 wk</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.59</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.50 â€“ 0.70</td>
<td class="Botrule" align="center" valign="bottom">&lt;0.001 (<a href="#footnote-1" class="Sup">*</a>)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom">Tumor Response (CR+PR)</td>
<td class="Botrule Rrule" align="center" valign="bottom">8.9%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.9%</td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom">&lt;0.001 ()</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="bottom">Response Duration</td>
<td class="Rrule" align="center" valign="bottom">Median<br>34.3 wk</td>
<td class="Rrule" align="center" valign="bottom">Median 15.9 wk</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Botrule" align="center" valign="bottom"></td>
</tr>
</tbody>
</table>
<p>Survival was evaluated in the intent-to-treat population. Figure 1 depicts the Kaplan-Meier curves for overall survival. The primary survival and PFS analyses were two-sided Log-Rank tests stratified by ECOG performance status, number of prior regimens, prior platinum, best response to prior chemotherapy.</p>
<div class="Figure"><img alt="image of Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=tarceva-02.jpg"></div>
<p><span class="Bold">Note:</span> HR is from Cox regression model with the following covariates: ECOG performance status, number of prior regimens, prior platinum, best response to prior chemotherapy. P-value is from two-sided Log-Rank test stratified by ECOG performance status, number of prior regimens, prior platinum, best response to prior chemotherapy.</p>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3E38A3DC-0BDA-4CD6-BD08-651B2A3228F2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 NSCLC - TARCEVA Administered Concurrently with Chemotherapy</h2>
<p class="First">Results from two, multicenter, placebo-controlled, randomized, trials in over 1000 patients conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel (TARCEVA, N = 526) or gemcitabine and cisplatin (TARCEVA, N = 580)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4AC5E867-63E2-4F5E-9D2E-8842B157D1F8"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Pancreatic Cancer - TARCEVA Administered Concurrently with Gemcitabine</h2>
<p class="First">The efficacy and safety of TARCEVA in combination with gemcitabine as a first-line treatment was assessed in a randomized, double blind, placebo-controlled trial in 569 patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients were randomized 1:1 to receive TARCEVA (100 mg or 150Â mg) or placebo once daily on a continuous schedule plus gemcitabine IV (1000 mg/m<span class="Sup">2</span>, Cycle 1 - Days 1, 8, 15, 22, 29, 36 and 43 of an 8 week cycle; Cycle 2 and subsequent cycles - Days 1, 8 and 15 of a 4 week cycle [the approved dose and schedule for pancreatic cancer, see the gemcitabine package insert]). TARCEVA or placebo was taken orally once daily until disease progression or unacceptable toxicity. The primary endpoint was survival. Secondary endpoints included response rate, and progression-free survival (PFS).  Duration of response was also examined.  The study was conducted in 18 countries.  A total of 285 patients were randomized to receive gemcitabine plus TARCEVA (261 patients in the 100 mg cohort and 24 patients in the 150 mg cohort) and 284 patients were randomized to receive gemcitabine plus placebo (260 patients in the 100 mg cohort and 24 patients in the 150 mg cohort). Too few patients were treated in the 150 mg cohort to draw conclusions.</p>
<p>Table 6 summarizes the demographic and disease characteristics of the study population that was randomized to receive 100 mg of TARCEVA plus gemcitabine or placebo plus gemcitabine. Baseline demographic and disease characteristics of the patients were similar between the 2 treatment groups, except for a slightly larger proportion of females in the TARCEVA arm (51%) compared with the placebo arm (44%). The median time from initial diagnosis to randomization was approximately 1.0 month. Most patients presented with <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> at study entry as the initial manifestation of pancreatic cancer.</p>
<a name="ID_32E46A45-ACEE-47D8-A6E8-5A23ACF161A8"></a><table cellpadding="0" frame="box" width="280.000">
<caption><span>Table 6: Demographic and Disease Characteristics: 100 mg Cohort</span></caption>
<col width="45.0%">
<col width="11.8%">
<col width="12.1%">
<col width="15.4%">
<col width="15.7%">
<tfoot><tr class="Last"><td class="Botrule" align="left" colspan="5" valign="top">*Unknown includes responses of 'Unknown' and missing.<br>**Stratification factor as documented at baseline; distribution differs slightly from values reported at time of randomization.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="bottom"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom"><span class="Bold">TARCEVA+ Gemcitabine<br><br>(N=261)</span></td>
<td class="Botrule" align="center" colspan="2" valign="bottom"><span class="Bold">Placebo + Gemcitabine <br><br>(N=260)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="bottom"><span class="Bold">Characteristics</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">(%)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">(%)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Gender</span></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule" align="right" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Female</td>
<td class="Botrule Rrule" align="right" valign="top">134</td>
<td class="Botrule Rrule" align="right" valign="top">(51)</td>
<td class="Botrule Rrule" align="right" valign="top">114</td>
<td class="Botrule" align="right" valign="top">(44)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Male</td>
<td class="Botrule Rrule" align="right" valign="top">127</td>
<td class="Botrule Rrule" align="right" valign="top">(49)</td>
<td class="Botrule Rrule" align="right" valign="top">146</td>
<td class="Botrule" align="right" valign="top">(56)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Age (Years)</span></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule" align="right" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â &lt;65</td>
<td class="Botrule Rrule" align="right" valign="top">136</td>
<td class="Botrule Rrule" align="right" valign="top">(52)</td>
<td class="Botrule Rrule" align="right" valign="top">138</td>
<td class="Botrule" align="right" valign="top">(53)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â â‰¥65</td>
<td class="Botrule Rrule" align="right" valign="top">125</td>
<td class="Botrule Rrule" align="right" valign="top">(48)</td>
<td class="Botrule Rrule" align="right" valign="top">122</td>
<td class="Botrule" align="right" valign="top">(47)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Race</span></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule" align="right" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Caucasian</td>
<td class="Botrule Rrule" align="right" valign="top">225</td>
<td class="Botrule Rrule" align="right" valign="top">(86)</td>
<td class="Botrule Rrule" align="right" valign="top">231</td>
<td class="Botrule" align="right" valign="top">(89)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Black</td>
<td class="Botrule Rrule" align="right" valign="top">8</td>
<td class="Botrule Rrule" align="right" valign="top">(3)</td>
<td class="Botrule Rrule" align="right" valign="top">5</td>
<td class="Botrule" align="right" valign="top">(2)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Asian</td>
<td class="Botrule Rrule" align="right" valign="top">20</td>
<td class="Botrule Rrule" align="right" valign="top">(8)</td>
<td class="Botrule Rrule" align="right" valign="top">14</td>
<td class="Botrule" align="right" valign="top">(5)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Other</td>
<td class="Botrule Rrule" align="right" valign="top">8</td>
<td class="Botrule Rrule" align="right" valign="top">(3)</td>
<td class="Botrule Rrule" align="right" valign="top">10</td>
<td class="Botrule" align="right" valign="top">(3)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">ECOG Performance Status*</span></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule" align="right" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â 0</td>
<td class="Botrule Rrule" align="right" valign="top">82</td>
<td class="Botrule Rrule" align="right" valign="top">(31)</td>
<td class="Botrule Rrule" align="right" valign="top">83</td>
<td class="Botrule" align="right" valign="top">(32)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â 1</td>
<td class="Botrule Rrule" align="right" valign="top">134</td>
<td class="Botrule Rrule" align="right" valign="top">(51)</td>
<td class="Botrule Rrule" align="right" valign="top">132</td>
<td class="Botrule" align="right" valign="top">(51)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â 2</td>
<td class="Botrule Rrule" align="right" valign="top">44</td>
<td class="Botrule Rrule" align="right" valign="top">(17)</td>
<td class="Botrule Rrule" align="right" valign="top">45</td>
<td class="Botrule" align="right" valign="top">(17)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Â Â Â Â Â Unknown*</td>
<td class="Botrule Rrule" align="right" valign="top">1</td>
<td class="Botrule Rrule" align="right" valign="top">(&lt;1)</td>
<td class="Botrule Rrule" align="right" valign="top">0</td>
<td class="Botrule" align="right" valign="top">(0)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Disease Status at Baseline**</span></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule Rrule" align="right" valign="top"></td>
<td class="Botrule" align="right" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Locally Advanced</td>
<td class="Botrule Rrule" align="right" valign="top">61</td>
<td class="Botrule Rrule" align="right" valign="top">(23)</td>
<td class="Botrule Rrule" align="right" valign="top">63</td>
<td class="Botrule" align="right" valign="top">(24)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Distant <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">Metastasis</span></td>
<td class="Rrule" align="right" valign="top">200</td>
<td class="Rrule" align="right" valign="top">(77)</td>
<td class="Rrule" align="right" valign="top">197</td>
<td class="Botrule" align="right" valign="top">(76)</td>
</tr>
</tbody>
</table>
<p>The results of the study are shown in Table 7.Â </p>
<a name="ID_F11465F4-C5BD-438F-B4F5-F8B38CB31E4A"></a><table border="single" cellpadding="0" frame="box" width="395.000">
<caption><span>Table 7: Efficacy Results: 100 mg Cohort</span></caption>
<col width="18.0%">
<col width="18.2%">
<col width="16.7%">
<col width="13.7%">
<col width="16.7%">
<col width="16.7%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Two-sided Log-Rank test stratified by ECOG performance status and extent of disease.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">TARCEVA + Gemcitabine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo+ Gemcitabine</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Hazard<br>Ratio ()</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">95%Â CI</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Survival</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Median</p>
<p>6.4 mo</p>250 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Median</p>
<p>6.0 mo</p>254 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></td>
<td class="Botrule Rrule" align="center" valign="top">0.81</td>
<td class="Botrule Rrule" align="center" valign="top">0.68 â€“ 0.97</td>
<td class="Botrule" align="center" valign="top">0.028 (<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">1-year Survival</td>
<td class="Botrule Rrule" align="center" valign="top">23.8%</td>
<td class="Botrule Rrule" align="center" valign="top">19.4%</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Progression-Free Survival</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Median</p>
<p>3.8 mo</p>225 events</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Median</p>
<p>3.5 mo</p>232 events</td>
<td class="Botrule Rrule" align="center" valign="top">0.76</td>
<td class="Botrule Rrule" align="center" valign="top">0.64 â€“ 0.92</td>
<td class="Botrule" align="center" valign="top">0.006 (<a href="#footnote-2" class="Sup">*</a>)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Tumor Response (CR+PR)</td>
<td class="Botrule Rrule" align="center" valign="top">8.6%</td>
<td class="Botrule Rrule" align="center" valign="top">7.9%</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top">0.87 ()</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Response Duration</td>
<td class="Rrule" align="center" valign="top">
<p class="First">Median</p>23.9 wk</td>
<td class="Rrule" align="center" valign="top">
<p class="First">Median</p>23.3 wk</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p>Survival was evaluated in the intent-to-treat population. Figure 2 depicts the Kaplan-Meier curves for overall survival in the 100 mg cohort. The primary survival and PFS analyses were two-sided Log-Rank tests stratified by ECOG performance status and extent of disease.</p>
<div class="Figure"><img alt="image of Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=tarceva-03.jpg"></div>
<p><span class="Bold">Note:</span> HR is from Cox regression model with the following covariates: ECOG performance status and extent of disease. P-value is from two-sided Log-Rank test stratified by ECOG performance status and extent of disease.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_F34EDA37-497E-4ECB-8E44-3ED760436196"></a><a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">25 mg Tablets</p>
<p>Round, biconvex face and straight sides, white film-coated, printed in orange with a â€œTâ€? and â€œ25â€? on one side and plain on the other side; supplied in:</p>
<a name="idaf0d82f-016f-460e-8b09-867bb78103bc"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5290-0<br>
</td>
</tr></tbody></table>
<p>Â </p>
<p>100 mg Tablets</p>
<p>Round, biconvex face and straight sides, white film-coated, printed in gray with â€œTâ€? and â€œ100â€? on one side and plain on the other side; supplied in:</p>
<a name="i5bb74862-cece-491e-8d5a-cc451070831e"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5474-0<br>
</td>
</tr></tbody></table>
<p>Â </p>
<p>150 mg Tablets</p>
<p>Round, biconvex face and straight sides, white film-coated, printed in maroon with â€œTâ€? and â€œ150â€? on one side and plain on the other side; supplied in:</p>
<a name="if989f51d-48f8-4124-88c4-cdded2aca972"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-5447-0<br>
</td>
</tr></tbody></table>
<p>Â </p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15Â° â€“ 30Â°C (59Â° â€“ 86Â°F). See USP Controlled Room Temperature. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_9ED4E48C-1645-4CC2-ACD0-3F244E11D179"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">If the following signs or symptoms occur, patients should be advised to seek medical advice promptlyÂ <span class="Italics">[see Warnings and Precautions (<a href="#i4i_warnings_precautions_ID_568ED0BC-9300-41EE-BBB2-A01AB0B5B726">5</a>), Adverse Reactions (<a href="#i4i_adverse_effects_ID_E7D1C058-2DF2-42D0-957D-BDA9FEAC877F">6</a>) and Dosage and Administration(<a href="#i4i_section_ID_7590F7A1-DD2C-4216-8995-497C4B573A91">2.3</a>)].</span></p>
<ul>
<li>Onset or worsening of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
<li>Severe or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>Onset or worsening of unexplained <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></li>
</ul>
<p>Given that <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> are anticipated when taking TARCEVA, proactive intervention may include alcohol-free emollient cream and sunscreen and the management of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> should be discussed with the patient.  This may include topical corticosteroids or antibiotics with anti-inflammatory properties.  These approaches were used in the NSCLC and pancreatic pivotal clinical trials.  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> preparations with drying properties may aggravate the <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>. Treatment of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has not been formally studied and should be based on <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> severity.  </p>
<p>Women of childbearing potential should be advised to avoid becoming pregnant while taking TARCEVAÂ <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_D2F3C49F-56A4-4CB0-86A0-0B1740C09D6B">5.8</a>) and Use in Specific Populations (<a href="#i4i_section_ID_A7A7A645-64A9-4833-A93B-F3A4D894AAA9">8.1</a>)].</span></p>
<p>Smokers should be advised to stop smoking while taking TARCEVA as plasma concentrations of erlotinib are reduced due to the effect of cigarette smoking <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_section_ID_E0E6F9C6-90EC-48A4-9993-C7694ACA7BA8">12.3 </a>)].</span></p>
<p>Â Â </p>
<p>Â </p>
<p><span class="Bold">Manufactured for:</span></p>
<p>OSI Pharmaceuticals Inc., Melville, NY 11747</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Schwarz Pharma Manufacturing, Seymour, IN 47274</p>
<p><span class="Bold">Distributed by:</span></p>
<p>Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B3AFA069-F408-4C38-9967-BC4ECB283AD9"></a><a name="section-16"></a><p></p>
<p class="First">For further information please call 1-877-TARCEVA (1-877-827-2382).</p>
<div class="Figure">
<img alt="image of Genetech logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=tarceva-04.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>TARCEVA and</p>
<div class="Figure">
<img alt="image of OSI logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=tarceva-05.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Â are trademarks of OSI Pharmaceuticals, Inc., Melville, NY, 11747, USA.</p>
<p>Â©2008 OSI Pharmaceuticals, Inc., and Genentech, Inc. All rights reserved.</p>
<p>Â </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First">Additional bar code label applied by:</p>
<p>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - PACKAGE LABEL</h1>
<p class="First"><span class="Bold">TARCEVA (erlotinib hydrochloride) tablet</span></p>
<p>25 mg</p>
<div class="Figure"><img alt="image of 25 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=5290.jpg"></div>
<p><br></p>
<p>100 mg</p>
<div class="Figure"><img alt="image of 100 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=5474.jpg"></div>
<p><br></p>
<p>150 mg</p>
<p><img alt="image of 150 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5783976b-0862-44e5-9b19-0f41d236d5c3&amp;name=5447.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TARCEVAÂ 		
					</strong><br><span class="contentTableReg">erlotinib hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5290(NDC:50242-062)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERLOTINIB HYDROCHLORIDE</strong> (ERLOTINIB) </td>
<td class="formItem">ERLOTINIB</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5290-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021743</td>
<td class="formItem">07/01/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TARCEVAÂ 		
					</strong><br><span class="contentTableReg">erlotinib hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5474(NDC:50242-063)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERLOTINIB HYDROCHLORIDE</strong> (ERLOTINIB) </td>
<td class="formItem">ERLOTINIB</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5474-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021743</td>
<td class="formItem">11/21/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TARCEVAÂ 		
					</strong><br><span class="contentTableReg">erlotinib hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5447(NDC:50242-064)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERLOTINIB HYDROCHLORIDE</strong> (ERLOTINIB) </td>
<td class="formItem">ERLOTINIB</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5447-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021743</td>
<td class="formItem">10/13/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fb809355-146a-4baf-a029-a80b7faee7bb</div>
<div>Set id: 5783976b-0862-44e5-9b19-0f41d236d5c3</div>
<div>Version: 1</div>
<div>Effective Time: 20120105</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
